Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases

Onkologie

Volumn 30, Issue 12, 2007, Pages 637-643

  Min, Byung Soh ^a   Kim, Nam Kyu ^a,b   Ahn, Jung Bai ^a   Roh, Jae Kyung ^a   Kim, Kyung Sik ^a   Choi, Jin Sub ^a   Cha, Seung Hwan ^a   Kim, Hogeun ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Cetuximab; Colorectal neoplasm; Irinotecan; Liver metastasis; Phase II study

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPOTENSION; LEUKOPENIA; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; TREATMENT OUTCOME;

EID: 37049036175     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109957     Document Type: Article

References (24)

1. Coleman MP, Esteve J, Arslan PDA, Renard H: Trend in cancer incidence and mortality. Lyon, IARC, 1993.
2. Sung JJ, Lau JY, Goh KL, Leung WK: Increasing incidence of colorectal cancer in asia: implications for screening. Lancet Oncol 2005;6:871-876.
3. Leonard GD, Brenner B, Kemeny NE: Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005;23:2038-2048.
4. Kelly H, Goldberg RM: Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005;23:4553-4560.
5. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-520; discussion 520-502.
6. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001;8:347-353.
7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
8. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208.
9. Rubio ED, Tabernero J, Cutsem Ev, Cervantes A, André T, Humblet Y, Soulié P, Corretgé S, Kisker O, Gramont Ad: Cetuximab in combination with oxaliplatin/5-fluorouracil (5-fu)/folinic acid (fa) (folfox-4) in the first-line treatment of patients with epidermal growth factor receptor (egfr)-expressing metastatic colorectal cancer: An international phase II study. J Clin Oncol 2005, ASCO Annual Meeting Proceedings 2005;23:3535.
10. Cutsem EV, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, Rougier P, Cunningham D, Nippgen J, Kohne C: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer: the crystal trial. J Clin Oncol 2007, ASCO Annual Meeting Proceedings Part I 2007;25:1.
11. National Cancer Institute: National cancer institute common toxicity criteria, version 2.0, 1998.
12. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:1311-1319.
13. Schull B, Kornek GV, Schmid K, Raderer M, Ulrich-Pur H, Fiebiger W, Schneeweiss B, Lenauer A, Depisch D, Scheithauer W: Second-line treatment of advanced colorectal cancer with a biweekly oxaliplatin plus irinotecan combination regimen. Onkologie 2002;25:358-362.
14. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a north central cancer treatment group phase II study. J Clin Oncol 2005;23:9243-9249.
15. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, Vellone M, Giuliante F, Nuzzo G, Barone C: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933-939.
16. Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Pollert P, Kohne CH: Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006;17:450-456.
17. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
18. Aloia T, Levi F, Wicherts DA, Haas RJ, Paule B, Bralet M, Bouchahda M, Azoulay D, Castaing D, Adam R: Hepatic resection following rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007, ASCO Annual Meeting Proceedings Part I 2007;25:1.
19. Vanhoefer U: Novel molecular approaches in the therapy of advanced colorectal carcinoma. Onkologie 2003;26(suppl 7):70-74.
20. Ellis LM, Curley SA, Grothey A: Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005;23:4853-4855.
21. Khatri VP, Petrelli NJ, Belghiti J: Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 2005;23:8490-8499.
22. Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V, Malka D, Pignon JP, Lasser P: Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005;12:900-909.
23. Berber E, Pelley R, Siperstein AE: Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 2005;23:1358-1364.
24. Abitabile P, Hartl U, Lange J, Maurer CA: Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 2007;33:67-71.